Article

Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers

Clinical Flow Cytometry Laboratory, University Health Network, Toronto, Canada.
Cytotherapy (Impact Factor: 3.1). 06/2009; 11(5):595-605. DOI: 10.1080/14653240902923161
Source: PubMed

ABSTRACT Enumeration of viable CD34(+) cells provides critical information for the bone marrow (BM) transplant physician. The single-platform ISHAGE protocol is the most reliable method currently available to quantitate accurately this important subset of cells. Previous studies have shown that 5 CD34(+) cells/microL blood predicts the collection of at least 0.5x10(6) CD34(+) cells/kg patient weight. From the apheresis product, infusion of 2.5x10(6) viable CD34(+) cells (measured pre-cryopreservation)/kg patient weight will reliably permit engraftment of the hematopoietic system (as measured by the time to 20000 platelets/microL) by day 12-14 post-infusion.
We compared the CD34(+) cell numbers derived from Flow Count-based Stem-Kit; (Beckman Coulter) and Trucount tube-based stem cell enumeration (SCE) kit (BD Biosciences) ISHAGE templates on BD FACSCalibur and BD FACSCanto cytometers on 12 granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood (MPB) and 10 peripheral blood stem cell (PBSC) samples.
Comparison of results showed that there was no statistical difference between samples run with Stem-Kit on the FACSCalibur versus SCE kit-based assays on either the FACSCalibur or FACSCanto. Mean results for the Stem-Kit/Calibur combination were 137, for SCE kit/Calibur 140 and for SCE kit/Canto 137 cells/microL. Pair-wise comparison of data based on rank order showed no statistically significant difference and all correlation coefficients had an R(2)>0.98.
The two kits generated very similar data on a range of fresh samples regardless of instrument platform. These results confirm and extend the utility of the single-platform ISHAGE protocols with a variety of reagent kits and instrument platforms.

9 Followers
 · 
593 Views
  • Source
    • "For those acquiring flow data with the use of automated software, it is essential that the cytometrist be aware of the potential presence of subsets of CD34 þ cells that play no documented role in engraftment. The auto-software itself cannot distinguish such subsets from candidate engrafting phenotypes, and, in such cases, manual analysis (performed after acquisition of data) is essential [9]. "
    Cytotherapy 03/2015; 17(5). DOI:10.1016/j.jcyt.2015.02.013 · 3.10 Impact Factor
  • Source
    • "Blood count was analyzed before and after apheresis from peripheral blood using a hematology analyzer (Sysmex , Norderstedt, Germany). CD34+ cells were counted in pre-and post-apheresis peripheral blood samples as well as in a product sample by flow cytometry using a commercially available single-platform assay (BD stem cell enumeration kit, BectonDickinson, Heidelberg, Germany) [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Three different apheresis systems were used in our center for the collection of peripheral blood progenitor cells (PBPCs): COM.TEC (Fresenius Healthcare), COBE Spectra, and Spectra Optia (both from Caridian BCT). We compared 131 autologous and 56 allogeneic apheresis procedures to elucidate feasibility and effectiveness of the different systems. Collection efficiacy varied significantly with lowest results obtained with COBE Spectra. COM.TEC and Spectra Optia produced lower WBC contamination than COBE Spectra, but at the expense of higher product volume and longer apheresis time. High collection efficacy and a low product volume may be favorable characteristics of the Spectra Optia.
    Transfusion and Apheresis Science 07/2013; 49(3). DOI:10.1016/j.transci.2013.06.002 · 1.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Double unit cord blood (CB) transplantation (CBT) appears to augment engraftment despite only one unit engrafting in most patients. We hypothesized that superior unit quality, as measured by a higher percentage of viable cells postthaw, would determine the engrafting unit. Therefore, we prospectively analyzed 46 double-unit transplants postthaw using flow cytometry with modified gating that included all dead cells. Using a 75% threshold (mean viability minus 2 SD), 20% of units had low CD34+ cell viability, with viability varying according to the bank of origin. Further, in the 44 patients with single unit engraftment, CD34+ cell viability was higher in engrafting units (P=.0016). Although either unit engrafted if both had high CD34+ viability, units with <75% viability were very unlikely to engraft: in 16 patients who received one high and one low CD34+ viability unit, only 1 of 16 units with viability <75% engrafted (P=.0006). Further, in the single patient without engraftment of either unit, both had CD34+ viability <75%. Finally, poor CD34+ viability correlated with lower colony forming units (CFUs) (P=.02). Our data suggests one mechanism by which double unit CBT can improve engraftment is by increasing the probability of transplanting at least one unit with adequate viability and the potential to engraft.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 11/2009; 16(4):500-8. DOI:10.1016/j.bbmt.2009.11.013 · 3.35 Impact Factor
Show more